Checkpoint blockade using anti CTLA-4 and anti PD-1 is effective in “hot” tumors like melanoma with pre-existing immune infiltrates (1); however, “cold” tumors like prostate cancer respond poorly. Here, RPL17 is linked to prostate cancer.